Lorlatinib in NSCLC: Robust Efficacy Seen.

Article Details

Citation
Copy to clipboard

Authors unspecified

Lorlatinib in NSCLC: Robust Efficacy Seen.

Cancer Discov. 2017 Dec;7(12):1360-1361. doi: 10.1158/2159-8290.CD-NB2017-153. Epub 2017 Nov 3.

PubMed ID
29101158 [ View in PubMed
]
Abstract

The investigational ALK inhibitor lorlatinib, whose early clinical activity was first reported last year, continues to look promising in advanced ALK-positive or ROS1-positive non-small cell lung cancer. In a phase II study, robust responses were seen in previously untreated patients, as well as those who had received as many as three prior ALK inhibitors.

DrugBank Data that Cites this Article

Drugs